Tumor necrosis factor-alpha (TNF-a) has been implicated in the immunological complications of stem cell transplantation (SCT) including graft-versus-host disease (GVHD). In this report of a patient undergoing allogeneic SCT for AML, serial cytokine measurements by real-time PCR revealed increased production of interferon-gamma (IFN-c) and TNF-a, but not interleukin (IL)-4 in purified T cells following withdrawal of immunosuppression. Cytokine changes were contemporaneous with the onset of nephrotic syndrome (NS), a rare manifestation of GVHD. These findings indicate that serial cytokine monitoring may allow for the prediction of GVHD during immunosuppression withdrawal and lend further insight into the pathogenesis of NS.
drome; TNF-a Nephrotic syndrome (NS) is a rare manifestation of graftversus-host disease (GVHD) and is usually seen in the context of other manifestations of GVHD including sclerodermatous skin changes, sicca syndrome and bronchiolitis obliterans.
1,2 Remission from NS is often achieved with reintroduction of cyclosporin, indicating that the glomerular lesion is likely to be induced by donor T cells.
Idiopathic NS is associated with excessive production of tumor necrosis factor-alpha (TNF-a). 3, 4 Similarly, production of TNF-a has been implicated in the development of gut and skin GVHD, and the induction of graft-versusleukemia effect. 5 In animal models of acute GVHD, lipopolysaccharide (LPS)-stimulated monocytes have been demonstrated as the major source of TNF-a production. 6 Specific production of TNF-a in purified T-cell populations has not been previously reported.
In this report, we describe the onset of NS in a 48-yearold woman 123 days following allogeneic stem cell transplantation (SCT) for early relapsed acute myeloid leukemia. Complete donor T-cell chimerism was established from 20 days after SCT. The onset of NS occurred during planned withdrawal of cyclosporin and was associated with an increase in TNF-a production by donor T cells. These findings demonstrate the potential utility of serial cytokine monitoring in patients undergoing allogeneic SCT and provide further evidence as to the immunological mechanisms of NS.
Methods

Patient samples
Approval for this study and reporting of these data were obtained by the Human Ethics Committee of Wellington Hospital. Peripheral blood was taken from the donor prior to transplant and from the recipient prior to transplant (day 0) and at days 20, 30, 40, 53, 64, 76, 84, 99, 123 and 170 post-SCT. Genomic DNA for chimerism analysis was extracted from 8-10 ml peripheral blood at each time-point using Chelex-100t (BioRad). T lymphocytes were purified (495% purity) from 4-10 ml of each peripheral blood sample with RosetteSept T-cell enrichment cocktail (StemCell Technologies). RNA was then isolated from 1 Â 10 6 -5 Â 10 6 T cells with Trizol s (Invitrogen) and total first-strand cDNA amplified using random hexamer primers and M-MLV Reverse Transcriptase (Invitrogen) according to the manufacturer's instructions. Samples of isolated T cells from two additional patients undergoing allogeneic SCT were also analyzed in an identical manner. These patients did not develop GVHD and had no evidence of proteinuria during their post-transplant course.
Chimerism analysis
Pre-SCT PCR was performed on the donor and recipient DNA with nine fluorescently labeled primer pairs designed to amplify regions containing short tandem repeats. An informative primer pair (vWA31) produced distinguishable PCR products from donor and recipient DNA. This primer pair was used subsequently in post-SCT PCR to determine the degree of donor T-cell engraftment. Donor and recipient PCR products were amplified post-BMT from the DNA isolated from recipient peripheral blood cells at each time point. The PCR products were separated and identified on an ABI 377 automated DNA sequencer (Applied Biosystems) and quantified using Genescan software (Applied Biosystems). The proportion of donor-specific PCR products was used to calculate the proportion of donor T cells in the recipient's peripheral blood.
Real-time PCR to quantify cytokine mRNA
At each of the time points above, cytokine (TNF-a, IFN-g and IL-4) and ribosomal 18S cDNA were quantified in isolated T cells using pre-developed assay reagents (PDARS) on an ABI Prismt 7700 sequence detection system, both from Applied Biosystems. cDNA was normalized by comparing the amount of 18S cDNA between samples. The presence of cytokine cDNA was quantified relative to the amount of cytokine cDNA found in the day 0 sample from the donor.
Case report
The patient presented 1 year prior to SCT with AML (FAB classification M2). No chromosomal abnormalities were detected in leukemic blasts. Remission induction was undertaken with standard multiagent chemotherapy (daunorubicin, cytarabine, thioguanine) and remission was consolidated with three further cycles of chemotherapy as per the MRC AML12 study protocol. 7 The third cycle of consolidation was complicated by the development of pulmonary nocardiasis, which was successfully treated with cotrimoxazole 960 mg twice daily. The duration of first complete remission was 12 months. Early relapse was confirmed on bone marrow aspirate following the development of pancytopenia. Further remission induction chemotherapy was not given. Pre-SCT conditioning with cyclophosphamide 120 mg/m 2 and 12 Gy total body irradiation was used followed by an allogeneic peripheral blood SCT from a fully HLAmatched brother. Anti-infective prophylaxis was with acyclovir 200 mg TDS and fluconazole 200 mg daily from day À1. Imepenem 500 mg 6 h was used as prophylaxis against Nocardia reactivation from the start of conditioning until engraftment after which time cotrimoxazole was reinstated. GVHD prophylaxis was with cyclosporin 3 mg/ kg/day as a divided intravenous infusion from day À1, methotrexate 10 mg/m 2 on days 1, 3, 6 and 11, and prednisone from day 14 as previously published 8 ( Figure 1b) .
Neutrophil recovery to 40.5 Â 10 9 /l was achieved by day 14, and unsupported platelet recovery to 420 Â 10 9 /l was achieved on day 16. Cytogenetic examination of bone marrow aspirates performed on days 28 and 100 confirmed 100% male cells. Chimerism analysis performed on isolated peripheral blood T lymphocytes confirmed 100% donor chimerism from day 20 to day 132 inclusive. In the absence of GVHD, cyclosporin withdrawal started on day 60 and was ceased on day 90 (Figure 1a) . On day 120, the patient first reported facial and ankle edema and serum albumin was measured at 26 g/l (Figure 1c) . A 24-h urine collection confirmed heavy proteinuria of 13 g/24 h (Figure 1d ). Renal biopsy revealed minimal change glomerulonephritis without a proliferative infiltrate (Figure 2 ). Cyclosporin 150 mg twice daily was restarted on day 130 by which time the serum albumin had fallen to 13 g/l (Figure 1c ). PCR revealed a small peak of TNF-a production at day 53 with a greater peak observed at day 123 (Figure 1e) . Similarly, peaks of IFN-g were seen at days 20, 53 and 123 (Figure 1f) . No significant increase in IL-4 production was observed at any time point (data not shown). Within 50 days of reinstating cyclosporin, the serum albumin had returned to the normal range, renal protein loss had diminished to 0.3 g/l and T-cell production of TNF-a and IFN-g had fallen to baseline. Other manifestations of acute or chronic GVHD have not occurred during the post-transplant course. Results of samples analyzed from two additional patients who did not develop signs of GVHD revealed no evidence of TNF-a production.
Discussion
This case report is the first to demonstrate an association between the TNF-a transcription from purified allogeneic T cells and the development of NS as a manifestation of GVHD. The serial measurement of TNF-a and IFN-g RNA production in isolated T cells has allowed not only insight into the pathogenesis of this unusual complication of SCT, but also provided a means by which to monitor immunological response to further immunosuppression withdrawal in patients undergoing allogeneic SCT.
In this patient, the presence of 100% donor T-cell chimerism confirms that TNF-a and IFN-g production was solely from engrafted donor T cells. The absence of T-cell infiltration on the renal biopsy would suggest that alloantigens contained within renal tissues may not have been the specific target of T-cell activation, rather that the glomerular injury was a consequence of cytokine production stimulated by alloantigens present at extrarenal sites. Indeed, animal models have demonstrated that the tissue damage produced by allogeneic T cells is a consequence of T-cell recognition of alloantigens presented by residual host antigen-presenting cells rather than by tissue targets themselves. 9 The previously published findings that TNF-a production is integral to the development of idiopathic NS would suggest that the onset of NS in our patient was a direct consequence of TNF-a production by engrafted donor T cells and was initiated by the withdrawal of immunosuppression.
The methods employed in the serial monitoring of this particular patient allow for detailed prospective immunological profiling of patients undergoing allogeneic SCT. By understanding the kinetics of cytokine production and Tcell engraftment in these patients, it may be possible to more accurately predict the onset of GVHD and modify immunosuppressive therapies accordingly. It is possible that the smaller peaks of TNF-a and IFN-g production seen at day 53 during prednisone withdrawal may have been predictive for the subsequent development of NS at day 123. In support of this conclusion is the finding that two additional patients undergoing allogeneic SCT who did not develop GVHD revealed no increase in TNF-a production at any time. Further analysis of cytokine profiles and onset of GVHD is an ongoing study of all patients receiving allogeneic SCT in our unit. Nephrotic syndrome post BMT associated with TNF-a production J Seconi et al
